Lincaína

Lidocaine Hydrochloride, the active ingredient in Lincaína, is a local anesthetic presented as a sterile solution for intramuscular and subcutaneous use. It provides reversible nerve blockade for minor surgical, diagnostic or dental procedures in adult patients.

GNH USA supplies Lincaína as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lincaína, a lidocaine‑based local anesthetic, is employed in procedures that require temporary loss of sensation.

- Minor surgical procedures: Provides rapid onset of surface anesthesia to facilitate incision and suturing. - Diagnostic interventions: Allows painless needle insertion for biopsies or catheter placements. - Dental treatments: Enables localized numbness for extractions, restorations or periodontal work.

Adverse reactions to Lincaína are generally related to its local anesthetic properties and formulation.

Common Side Effects: - Injection site pain - Erythema or swelling - Transient tingling or numbness - Metallic taste - Mild dizziness

Serious or Rare Side Effects: - Systemic toxicity (central nervous system depression, seizures) - Cardiac arrhythmias - Allergic reactions (urticaria, anaphylaxis) - Methemoglobinemia (rare) - Persistent numbness

When using Lincaína, clinicians should observe several safety measures.

- Patient assessment: Verify no known hypersensitivity to amide‑type local anesthetics. - Dose calculation: Adjust dose for body weight and avoid exceeding maximum recommended limits. - Cardiovascular status: Use caution in patients with cardiac conduction disorders. - Concurrent CNS depressants: Monitor for additive central nervous system effects. - Pregnancy and lactation: Use only if benefit outweighs potential risk; data limited. - Store below 25°C: Keep in original container, protect from moisture and light.

Lincaína may interact with other medicines; awareness of the interaction level guides management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): May potentiate cardiotoxicity. - CYP3A4 inhibitors (e.g., ketoconazole): Can increase systemic lidocaine levels. - Beta‑blockers: May enhance bradycardic effects when systemic absorption occurs.

Moderate Interactions (Monitor Closely): - Other local anesthetics: Cumulative toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids): May augment sedation. - Diuretics (e.g., furosemide): May alter plasma protein binding.